Extramedullary Relapse of Acute Myeloid Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation: An Easily Overlooked but Significant Pattern of Relapse

Biology of Blood and Marrow Transplantation

Volumn 18, Issue 12, 2012, Pages 1800-1807

  Yoshihara, Satoshi ^a   Ando, Toshihiko ^b   Ogawa, Hiroyasu ^a  

^a HYOGO COLLEGE OF MEDICINE   (Japan)

^b Yamaguchi Grand Medical Center   (Japan)

Author keywords

Acute myeloid leukemia; Extramedullary relapse; FDG PET CT; Graft versus leukemia effect

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; CHRONIC GRAFT VERSUS HOST DISEASE; DONOR LYMPHOCYTE INFUSION; GRAFT VERSUS LEUKEMIA EFFECT; HUMAN; IMMUNOMODULATION; LEUKEMIA RELAPSE; PATHOGENESIS; POSITRON EMISSION TOMOGRAPHY; REVIEW;

HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOID, ACUTE; LEUKEMIC INFILTRATION; PROGNOSIS; RECURRENCE;

EID: 84869090991     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2012.05.010     Document Type: Review

References (76)

1. Koreth J., Schlenk R., Kopecky K.J., et al. Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials. JAMA 2009, 301:2349-2361.
2. Duval M., Klein J.P., He W., et al. Hematopoietic stem-cell transplantation for acute leukemia in relapse or primary induction failure. J Clin Oncol 2010, 28:3730-3738.
3. Pavletic S.Z., Kumar S., Mohty M., et al. NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: report from the Committee on the Epidemiology and Natural History of Relapse following Allogeneic Cell Transplantation. Biol Blood Marrow Transplant 2010, 16:871-890.
4. Bakst R.L., Tallman M.S., Douer D., Yahalom J. How I treat extramedullary acute myeloid leukemia. Blood 2011, 118:3785-3793.
5. Békássy A.N., Hermans J., Gorin N.C., Gratwohl A. Granulocytic sarcoma after allogeneic bone marrow transplantation: a retrospective European multicenter survey. Acute and Chronic Leukemia Working Parties of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 1996, 17:801-808.
6. Clark W.B., Strickland S.A., Barrett A.J., Savani B.N. Extramedullary relapses after allogeneic stem cell transplantation for acute myeloid leukemia and myelodysplastic syndrome. Haematologica 2010, 95:860-863.
7. Simpson D.R., Nevill T.J., Shepherd J.D., et al. High incidence of extramedullary relapse of AML after busulfan/cyclophosphamide conditioning and allogeneic stem cell transplantation. Bone Marrow Transplant 1998, 22:259-264.
8. Chong G., Byrnes G., Szer J., Grigg A. Extramedullary relapse after allogeneic bone marrow transplantation for haematological malignancy. Bone Marrow Transplant 2000, 26:1011-1015.
9. Lee K.H., Lee J.H., Choi S.J., et al. Bone marrow vs extramedullary relapse of acute leukemia after allogeneic hematopoietic cell transplantation: risk factors and clinical course. Bone Marrow Transplant 2003, 32:835-842.
10. Blum W., Penza S., Farag S., et al. Incidence of extramedullary relapse of acute myeloid leukemia following transplantation with busulfan-based conditioning regimens. ASH Annual Meeting Abstracts 2004, 104:5123.
11. Shimoni A., Rand A., Hardan I., et al. Isolated extra-medullary relapse of acute leukemia after allogeneic stem-cell transplantation; different kinetics and better prognosis than systemic relapse. 50th ASH Annual Meeting and Exposition 2008, abstract 2148.
12. Harris A.C., Mageneau J., Braun T., et al. Extramedullary relapse in acute leukemia following allogeneic hematopoietic stem cell transplantation: incidence, risk factors and outcomes. Biol Blood Marrow Transplant 2010, 16:S177-S178.
13. Porter D.L., Alyea E.P., Antin J.H., et al. NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant 2010, 16:1467-1503.
14. Kogut N.M., Palmer J., Tsai N.-C., et al. Extramedullary relapse following reduced intensity alloHCT for adult AML. ASH Annual Meeting Abstracts 2010, abstract 3467.
15. Yoshihara S., Ikegame K., Kaida K., et al. Incidence of extramedullary relapse after haploidentical SCT for advanced AML/myelodysplastic syndrome. Bone Marrow Transplant 2012, 47:669-676.
16. Solh M., DeFor T.E., Weisdorf D.J., Kaufman D.S. Extramedullary relapse of acute myelogenous leukemia after allogeneic hematopoietic stem cell transplantation: better prognosis than systemic relapse. Biol Blood Marrow Transplant 2012, 18:106-112.
17. Potenza L., Luppi M., Riva G., et al. Isolated extramedullary relapse after autologous bone marrow transplantation for acute myeloid leukemia: case report and review of the literature. Am J Hematol 2006, 81:45-50.
18. Choi S.J., Lee J.H., Lee J.H., et al. Treatment of relapsed acute myeloid leukemia after allogeneic bone marrow transplantation with chemotherapy followed by G-CSF-primed donor leukocyte infusion: a high incidence of isolated extramedullary relapse. Leukemia 2004, 18:1789-1797.
19. Singhal S., Powles R., Kulkarni S., Treleaven J., Saso R., Mehta J. Long-term follow-up of relapsed acute leukemia treated with immunotherapy after allogeneic transplantation: the inseparability of graft-versus-host disease and graft-versus-leukemia, and the problem of extramedullary relapse. Leuk Lymphoma 1999, 32:505-512.
20. Takami A., Okumura H., Yamazaki H., et al. Prospective trial of high-dose chemotherapy followed by infusions of peripheral blood stem cells and dose-escalated donor lymphocytes for relapsed leukemia after allogeneic stem cell transplantation. Int J Hematol 2005, 82:449-455.
21. Tallman M.S., Hakimian D., Shaw J.M., Lissner G.S., Russell E.J., Variakojis D. Granulocytic sarcoma is associated with the 8;21 translocation in acute myeloid leukemia. J Clin Oncol 1993, 11:690-697.
22. Byrd J.C., Edenfield W.J., Shields D.J., Dawson N.A. Extramedullary myeloid cell tumors in acute nonlymphocytic leukemia: a clinical review. J Clin Oncol 1995, 13:1800-1816.
23. Baer M.R., Stewart C.C., Lawrence D., et al. Expression of the neural cell adhesion molecule CD56 is associated with short remission duration and survival in acute myeloid leukemia with t(8;21)(q22;q22). Blood 1997, 90:1643-1648.
24. Chang H., Brandwein J., Yi Q.L., Chun K., Patterson B., Brien B. Extramedullary infiltrates of AML are associated with CD56 expression, 11q23 abnormalities and inferior clinical outcome. Leukemia Res 2004, 28:1007-1011.
25. Ito S., Ishida Y., Oyake T., et al. Clinical and biological significance of CD56 antigen expression in acute promyelocytic leukemia. Leuk Lymphoma 2004, 45:1783-1789.
26. Montesinos P., Rayon C., Vellenga E., et al. Clinical significance of CD56 expression in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based regimens. Blood 2011, 117:1799-1805.
27. Mortimer J., Blinder M.A., Schulman S., et al. Relapse of acute leukemia after marrow transplantation: natural history and results of subsequent therapy. J Clin Oncol 1989, 7:50-57.
28. Au W.Y., Chan A.C., Lie A.K., Chen F.E., Liang R., Kwong Y.L. Recurrent isolated extramedullary relapses as granulocytic sarcomas following allogeneic bone marrow transplantation for acute myeloid leukemia. Bone Marrow Transplant 1998, 21:205-208.
29. Cunningham I. Extramedullary sites of leukemia relapse after transplant. Leuk Lymphoma 2006, 47:1754-1767.
30. Kamada Y., Suzukawa K., Taoka K., Okoshi Y., Hasegawa Y., Chiba S. Relapse of acute myeloid leukemia with t(16;21)(p11;q22) mimicking autoimmune pancreatitis after second allogeneic bone marrow transplantation. ISRN Hematol 2011, 2011:285487.
31. Kolb H.J. Graft-versus-leukemia effects of transplantation and donor lymphocytes. Blood 2008, 112:4371-4383.
32. Lee J.H., Choi S.J., Seol M., et al. Anti-leukemic effect of graft-versus-host disease on bone marrow and extramedullary relapses in acute leukemia. Haematologica 2005, 90:1380-1388.
33. Jiang Y.Z., Cullis J.O., Kanfer E.J., Goldman J.M., Barrett A.J. T cell and NK cell mediated graft-versus-leukaemia reactivity following donor buffy coat transfusion to treat relapse after marrow transplantation for chronic myeloid leukaemia. Bone Marrow Transplant 1993, 11:133-138.
34. Berthou C., Leglise M.C., Herry A., et al. Extramedullary relapse after favorable molecular response to donor leukocyte infusions for recurring acute leukemia. Leukemia 1998, 12:1676-1681.
35. Chakraverty R., Cote D., Buchli J., et al. An inflammatory checkpoint regulates recruitment of graft-versus-host reactive T cells to peripheral tissues. J Exp Med 2006, 203:2021-2031.
36. Stölzel F., Hackmann K., Kuithan F., et al. Clonal evolution including partial loss of human leukocyte antigen genes favoring extramedullary acute myeloid leukemia relapse after matched related allogeneic hematopoietic stem cell transplantation. Transplantation 2012, 93:744-749.
37. Vago L., Perna S.K., Zanussi M., et al. Loss of mismatched HLA in leukemia after stem-cell transplantation. N Engl J Med 2009, 361:478-488.
38. Villalobos I.B., Takahashi Y., Akatsuka Y., et al. Relapse of leukemia with loss of mismatched HLA resulting from uniparental disomy after haploidentical hematopoietic stem cell transplantation. Blood 2010, 115:3158-3161.
39. Bonnet D., Warren E.H., Greenberg P.D., Dick J.E., Riddell S.R. CD8(+) minor histocompatibility antigen-specific cytotoxic T lymphocyte clones eliminate human acute myeloid leukemia stem cells. Proc Natl Acad Sci U S A 1999, 96:8639-8644.
40. Farag S.S., Fehniger T.A., Ruggeri L., Velardi A., Caligiuri M.A. Natural killer cell receptors: new biology and insights into the graft-versus-leukemia effect. Blood 2002, 100:1935-1947.
41. Lanier L.L., Testi R., Bindl J., Phillips J.H. Identity of Leu-19 (CD56) leukocyte differentiation antigen and neural cell adhesion molecule. J Exp Med 1989, 169:2233-2238.
42. Garin-Chesa P., Fellinger E.J., Huvos A.G., et al. Immunohistochemical analysis of neural cell adhesion molecules. Differential expression in small round cell tumors of childhood and adolescence. Am J Pathol 1991, 139:275-286.
43. Kuenzle K., Taverna C., Steinert H.C. Detection of extramedullary infiltrates in acute myelogenous leukemia with whole-body positron emission tomography and 2-deoxy-2-[18F]-fluoro-D-glucose. Mol Imaging Biol 2002, 4:179-183.
44. Karlin L., Itti E., Pautas C., et al. PET-imaging as a useful tool for early detection of the relapse site in the management of primary myeloid sarcoma. Haematologica 2006, 91(12 suppl):ECR54.
45. Mantzarides M., Bonardel G., Fagot T., et al. Granulocytic sarcomas evaluated with F-18-fluorodeoxyglucose PET. Clin Nucl Med 2008, 33:115-117.
46. Aschoff P., Häntschel M., Oksüz M., et al. Integrated FDG-PET/CT for detection, therapy monitoring and follow-up of granulocytic sarcoma. Initial results. Nuklearmedizin 2009, 48:185-191.
47. Rao S., Langston A., Galt J.R., Halkar R.K. Extramedullary acute myeloid leukemia and the use of FDG-PET/CT. Clin Nucl Med 2009, 34:365-366.
48. Suga K., Kawakami Y., Hiyama A., Takeda K., Tanizawa Y., Matsunaga N. F-18 FDG PET/CT findings in a case of gastric relapse of acute myeloblastic leukemia. Clin Nucl Med 2009, 34:788-790.
49. von Falck C., Laenger F., Knapp W.H., Galanski M. F-18 FDG PET/CT showing bilateral breast involvement in acute myeloid leukemia relapse. Clin Nucl Med 2009, 34:713-715.
50. Ueda K., Ichikawa M., Takahashi M., Momose T., Ohtomo K., Kurokawa M. FDG-PET is effective in the detection of granulocytic sarcoma in patients with myeloid malignancy. Leukemia Res 2010, 34:1239-1241.
51. Choi E.R., Ko Y.H., Kim S.J., et al. Gastric recurrence of extramedullary granulocytic sarcoma after allogeneic stem cell transplantation for acute myeloid leukemia. J Clin Oncol 2010, 28:e54-e55.
52. Yoo S.W., Chung E.J., Kim S.Y., et al. Multiple extramedullary relapses without bone marrow involvement after second allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia. Pediatr Transplant 2012, 16:E125-E129.
53. Gunawardana D.H., Grigg A. Use of 18F-fluorodeoxyglucose positron emission tomography to change management and assess response to therapy in post-transplant extramedullary relapse of acute myeloid leukaemia. Intern Med J 2010, 40:466-467.
54. Stölzel F., Röllig C., Radke J., et al. 18F-FDG-PET/CT for detection of extramedullary acute myeloid leukemia. Haematologica 2011, 96:1552-1556.
55. Yoshihara S., Tamaki H., Ikegame K., et al. Early prediction of extramedullary relapse of leukemia following allogeneic stem cell transplantation using the WT1 transcript assay. Biol Blood Marrow Transplant 2006, 12:86.
56. Tamaki H., Yoshihara S., Fujioka T., Kawakami M., Oka Y., Ogawa H. Molecular detection of AML1-MTG8-positive cells in peripheral blood from a patient with isolated extramedullary relapse of t(8;21) acute myeloid leukemia. Leukemia 2009, 23:424-426.
57. Inoue K., Ogawa H., Yamagami T., et al. Long-term follow-up of minimal residual disease in leukemia patients by monitoring WT1 (Wilms tumor gene) expression levels. Blood 1996, 88:2267-2278.
58. Kwon M., Martínez-Laperche C., Infante M., et al. Evaluation of minimal residual disease by real-time quantitative PCR of Wilms' tumor 1 expression in patients with acute myelogenous leukemia after allogeneic stem cell transplantation: correlation with flow cytometry and chimerism. Biol Blood Marrow Transplant 2012, [Epub ahead of print].
59. Ando T., Mitani N., Matsui K., et al. Recurrent extramedullary relapse of acute myelogenous leukemia after allogeneic hematopoietic stem cell transplantation in a patient with the chromosomal abnormality t(8;21) and CD56-positivity. Int J Hematol 2009, 90:374-377.
60. Koc Y., Miller K.B., Schenkein D.P., Daoust P., Sprague K., Berkman E. Extramedullary tumors of myeloid blasts in adults as a pattern of relapse following allogeneic bone marrow transplantation. Cancer 1999, 85:608-615.
61. Neumann M., Blau I.W., Burmeister T., et al. Intrathecal application of donor lymphocytes in leukemic meningeosis after allogeneic stem cell transplantation. Ann Hematol 2011, 90:911-916.
62. Ustun C., Arat M., Celebi H., et al. Extramedullary relapse following allogeneic stem cell transplantation in acute promyelocytic leukemia: the role of ATRA. Haematologica 2001, 86:E31.
63. Kai T., Kimura H., Shiga Y., Ogawa K., Sato H., Maruyama Y. Recurrent extramedullary relapse of acute promyelocytic leukemia after allogeneic stem cell transplantation: successful treatment by arsenic trioxide in combination with local radiotherapy. Int J Hematol 2006, 83:337-340.
64. Pinto A., Maio M., Attadia V., Zappacosta S., Cimino R. Modulation of HLA-DR antigens expression in human myeloid leukaemia cells by cytarabine and 5-aza-2'-deoxycytidine. Lancet 1984, 2:867-868.
65. Pinto A., Attadia V., Fusco A., Ferrara F., Spada O.A., Di Fiore P.P. 5-Aza-2'-deoxycytidine induces terminal differentiation of leukemic blasts from patients with acute myeloid leukemias. Blood 1984, 64:922-929.
66. Momparler R.L., Bouchard J., Samson J. Induction of differentiation and inhibition of DNA methylation in HL-60 myeloid leukemic cells by 5-AZA-2'-deoxycytidine. Leukemia Res 1985, 9:1361-1366.
67. Coral S., Sigalotti L., Gasparollo A., et al. Prolonged upregulation of the expression of HLA class I antigens and costimulatory molecules on melanoma cells treated with 5-aza-2'-deoxycytidine (5-AZA-CdR). J Immunother 1999, 22:16-24.
68. Jabbour E., Giralt S., Kantarjian H., et al. Low-dose azacitidine after allogeneic stem cell transplantation for acute leukemia. Cancer 2009, 115:1899-1905.
69. Singh S.N., Cao Q., Gojo I., Rapoport A.P., Akpek G. Durable complete remission after single agent decitabine in AML relapsing in extramedullary sites after allo-SCT. Bone Marrow Transplant 2011, [Epub ahead of print].
70. Owonikoko T., Agha M., Balassanian R., Smith R., Raptis A. Gemtuzumab therapy for isolated extramedullary AML relapse following allogeneic stem-cell transplant. Nat Clin Pract Oncol 2007, 4:491-495.
71. Ando T., Mitani N., Matsunaga K., et al. Gemtuzumab ozogamicin therapy for isolated extramedullary AML relapse after allogeneic hematopoietic stem-cell transplantation. Tohoku J Exp Med 2010, 220:121-126.
72. Petersdorf S., Kopecky K., Stuart R.K., et al. Preliminary results of Southwest Oncology Group Study S0106: an international intergroup phase 3 randomized trial comparing the addition of gemtuzumab ozogamicin to standard induction therapy versus standard induction therapy followed by a second randomization to post-consolidation gemtuzumab ozogamicin versus no additional therapy for previously untreated acute myeloid leukemia. ASH Annual Meeting Abstracts 2009, abstract 790.
73. Estey E. Treatment of AML: resurrection for gemtuzumab ozogamicin?. Lancet 2012, 379:1468-1469.
74. Castaigne S., Pautas C., Terre C., et al. Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study. Lancet 2012, 379:1508-1516.
75. Tassone P., Gozzini A., Goldmacher V., et al. In vitro and in vivo activity of the maytansinoid immunoconjugate huN901-N2'-deacetyl-N2'-(3-mercapto-1-oxopropyl)-maytansine against CD56+ multiple myeloma cells. Cancer Res 2004, 64:4629-4636.
76. Ishitsuka K., Jimi S., Goldmacher V.S., Ab O., Tamura K. Targeting CD56 by the maytansinoid immunoconjugate IMGN901 (huN901-DM1): a potential therapeutic modality implication against natural killer/T cell malignancy. Br J Haematol 2008, 141:129-131.